NRX Pharmaceuticals宣布FDA批准扩大使用协议,将D-环丝氨酸为基础的NRX-101用于增强经颅磁刺激治疗抑郁症

美股速递
Jun 22

NRX Pharmaceuticals宣布,美国食品药品监督管理局(FDA)已批准一项扩大使用协议,允许将基于D-环丝氨酸的NRX-101药物,作为经颅磁刺激治疗抑郁症方案的增强剂。

这项协议意味着,符合条件的患者将能够提前获得这种尚在临床研究阶段的治疗组合。NRX-101是一种口服药物,旨在增强经颅磁刺激的神经可塑性效应,从而可能为对现有疗法反应不佳的抑郁症患者提供新的希望。

扩大使用协议通常适用于患有严重或危及生命疾病的患者,且当没有可比或令人满意的替代疗法时。此举为部分患者提供了在药物正式获批上市前接受潜在有效治疗的途径。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10